scholarly journals EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma

2009 ◽  
Vol 45 (9) ◽  
pp. 1700-1708 ◽  
Author(s):  
Michael Ryott ◽  
Darawalee Wangsa ◽  
Kerstin Heselmeyer-Haddad ◽  
Johan Lindholm ◽  
Göran Elmberger ◽  
...  
2004 ◽  
Vol 65 (9-10) ◽  
pp. S117
Author(s):  
Dianne De Santis ◽  
Marcel Tilanus ◽  
Dick van Wichen ◽  
Yvonne Arts ◽  
Marja Blokland ◽  
...  

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Yanqiu Wang ◽  
Zhengzeng Jiang ◽  
Chen Xu ◽  
Hao Wang ◽  
Lijie Tan ◽  
...  

2020 ◽  
Author(s):  
Xuhui Dong ◽  
Lei Yuan ◽  
Liangqing Yao

Abstract Background: Malignant transformation such as ovarian squamous cell carcinoma (SCC) in ovarian mature cystic teratoma (OMCT) is a rare tumor. The gene mutation of ovarian SCC remains unclear. We herein report a recurrent case of ovarian squamous cell carcinoma with MET gene copy number variation. Case presentation: A 60-year-old woman presented with recurrence of ovarian SCC 8 months after primary surgery. Adhesiolysis, right abdominal wall mass excision, prosthetics, enterectomy, enterostomy and partial cystectomy were performed by laparoscope. Pathologic examination demonstrated metastatic squamous cell carcinoma in ileocecus, rectum and abdominal wall muscle. MET gene copy number was elevated with copy number of six in this case. Postoperatively, the patient was treated with four cycles of combination chemotherapy with docetaxel and carboplatin. The patient was free of disease at 20 months’ follow-up. Conclusions: Optimal cytoreductive surgery combined with platinum-based chemotherapy is recommended currently for not only primary tumor but also recurrence. For patients with malignant transformation in OMCT, prompt diagnosis and individualized treatment are crucial for better prognosis. Increased copy number of MET may be correlated with her poor PFS and can be a potential therapeutic target for this case.


2007 ◽  
Vol 25 (16) ◽  
pp. 2184-2190 ◽  
Author(s):  
Mark Agulnik ◽  
Gilda da Cunha Santos ◽  
David Hedley ◽  
Trudey Nicklee ◽  
Patricia Pintor dos Reis ◽  
...  

Purpose Pharmacodynamic tissue studies were conducted on a phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Levels of epidermal growth factor receptor (EGFR), downstream signaling components, and markers of angiogenesis and apoptosis were evaluated to determine the relationship between correlative end points and clinical outcomes. Patients and Methods Pretreatment and during-treatment tumor and skin biopsies, and archival tumor specimens were evaluated for EGFR, phosphorylated (p) -EGFR, extracellular signal-regulated kinase (ERK), p-ERK, Akt, p-Akt, Ki67, p27, p-nuclear factor kappa B (NFκB), p-signal transducer and activator of transcription 3 (STAT3), and EGFR gene copy number. Results On 37 archival samples, response to therapy was evident in two of four (50%) patients with high EGFR gene copy number tumors and in four of 27 (15%) patients with low gene copy number tumors. On nine paired tumor biopsies, elevated pretreatment levels of p27 and p-STAT3 predicted for prolonged time to progression (TTP) and overall survival (OS; P ≤ .03). With treatment, a decrease in p-EGFR, p-NFκB, and p27 correlated with increased TTP, OS, or both TTP and OS, respectively (P ≤ .04). Multidimensional scaling (MDS) models revealed clustering profiles of tumor markers by immunofluorescence could predict response. On 32 paired skin biopsies, suppression of p-EGFR with therapy correlated with increased OS (P = .045). Conclusion High EGFR gene copy in tumor specimens may predict which patients have an increased likelihood of response to erlotinib, and decreased p-EGFR level in skin biopsies during therapy may represent a potential surrogate marker for improved clinical outcome. MDS represents a novel way to evaluate the relationships between molecular markers and clinical outcome. Additional biomarker studies with larger sample sizes are required to elucidate HNSCC patients who may benefit from this targeted therapy.


2006 ◽  
Vol 12 (11) ◽  
pp. 3272-3279 ◽  
Author(s):  
Marta Canel ◽  
Pablo Secades ◽  
Juan-Pablo Rodrigo ◽  
Rubén Cabanillas ◽  
Agustín Herrero ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document